Therefore, CD4– iNKT cells could serve as a potential target for immunotherapy, and strategies to exploit their function, such as the use of Tim-1–activating monoclonal Abs, should be explored as a possible therapeutic option for management of nonallergic asthma. This evidence concerns the gene CD4 and asthma.